STOCK TITAN
  1. Home
  2. News
  3. XENE

Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BURNABY, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 pm Eastern time.

A webcast will be available on the investors section of the Xenon website at http://investor.xenon-pharma.com and will be available for replay following the event.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com


Stock XENE logo
Xenon Pharmaceuticals Inc.

NASDAQ:XENE

XENE Rankings

#1612 Ranked by Market Cap
#3064 Ranked by Stock Gains
N/A Ranked by Dividends

XENE Latest News

May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
May 7, 2024
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 2, 2024
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
Apr 16, 2024
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

XENE Stock Data

2.94B
69.56M
0.38%
99.99%
3.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BURNABY

About XENE

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.